Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Systematic Literature Review of the Indirect Costs, Humanistic Burden, Patient or Caregiver Preference, and Qualitative Outcomes in Beta-Thalassemia

Yesim Aydinok, Sneha Purushotham, Aylin Yucel, Sohan Deshpande, Barbara Potrata, Myrto Trapali, Mrinalini Dixit, Farrukh Shah

Blood (2021) 138 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2021-145290

Published: 2021

Journal Articles

A Phase 2a Study Evaluating the Safety and Pharmacokinetics (PK) of Luspatercept in Pediatric Patients with Transfusion-Dependent β-Thalassemia (TDT)

Vip Viprakasit, Thomas D. Coates, Khaled M. Musallam, Julie Vienne Buerki, Meera Patturajan, Natalia Holot, Yesim Aydinok

Blood (2021) 138 (Supplement 1): 4161.

https://doi.org/10.1182/blood-2021-145698

Published: 2021

Journal Articles

Is Normal Growth and Development Achieved By Current Management Approaches to Thalassemia Major in the New Era?

Yesim Aydinok, MD, Vagif Samadli, MD, Nihal Karadas, MD, Hamiyet Ozdemir, MD, Deniz Karapinar, MD, Banu Yurekli, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-141069

Published: 2020

Journal Articles

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

Blood (2018) 132 (Supplement 1): 163.

https://doi.org/10.1182/blood-2018-163

Published: 2018

Journal Articles

Hemoglobin Utilization in Asplenic and Non-Splenectomized Transfusion Dependent Thalassemia Patients Supported with Pathogen Reduced Red Blood Cell Concentrates in a Phase 3 Study (SPARC)

Yesim Aydinok, Antonio Piga, Raffaella Origa, MD, Nina Mufti, PhD, Anna Erikson, PhD, Anne North, PhD, Katie Waldhaus, Christine Ernst, MD, Jin-Sying Lin, PhD, Norman Huang, PhD, Richard J. Benjamin, MD, Laurence Corash, MD

Blood (2018) 132 (Supplement 1): 3812.

https://doi.org/10.1182/blood-2018-99-112685

Published: 2018

Journal Articles

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

Ali T. Taher, Zeynep Karakas, Elena Cassinerio, Noppadol Siritanaratkul, Antonis Kattamis, Aurelio Maggio, Stefano Rivella, Norbert Hollaender, Bruyère Mahuzier, Brian Gadbaw, Yesim Aydinok

Blood (2018) 131 (2): 263–265.

https://doi.org/10.1182/blood-2017-06-790121

Published: 2018

Includes: Supplemental data

Journal Articles

A Randomised 1 Year Study Evaluating the Impact of Vitamin C Supplementation on Systemic Iron Parameters of Iron Overload in Thalassemia Major Patients on Long-Term Treatment with Deferasirox

Yesim Aydinok, MD, Metin Delebe, MD, Gunes Basol, MD, Selen Bayraktaroglu, MD, Nihal Karadas, MD, Burcu Barutcuoglu, MD, Eser Sozmen, MD, Zvi Ioav Cabantchik, MD PhD

Blood (2016) 128 (22): 1288.

https://doi.org/10.1182/blood.V128.22.1288.1288

Published: 2016

Journal Articles

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Yesim Aydinok, MD, Zeynep Karakas, MD, Elena Cassinerio, MD, Noppadol Siritanaratkul, MD, Antonis Kattamis, MD, Aurelio Maggio, MD, Norbert Hollaender, PhD, Bruyère Mahuzier, Pharm D, Brian Gadbaw, MD, Ali T. Taher, MD PhD

Blood (2016) 128 (22): 852.

https://doi.org/10.1182/blood.V128.22.852.852

Published: 2016

Journal Articles

Efficacy and Safety of Deferasirox in Chinese Patients with Non-Transfusion-Dependent Thalassemia: 1-Year Results from the Thetis Study

Yong-Rong Lai, Rong Rong Liu, M Domenica Cappellini, Yesim Aydinok, John B Porter, Zewen Zhu, Candace Wang, Xue Qi, Ali T Taher

Blood (2015) 126 (23): 4570.

https://doi.org/10.1182/blood.V126.23.4570.4570

Published: 2015

Journal Articles

Efficacy and Safety of Deferasirox Across Underlying Non-Transfusion-Dependent Thalassemia Syndromes: 1-Year Results from the Thetis Study

M Domenica Cappellini, Vip Viprakasit, Yesim Aydinok, John B Porter, Yong-Rong Lai, Noppadol Siritanaratkul, Zeynep Karakas, Antonis Kattamis, Candace Wang, Zewen Zhu, Felicity Schaefer, Ali T Taher

Blood (2015) 126 (23): 3366.

https://doi.org/10.1182/blood.V126.23.3366.3366

Published: 2015

Journal Articles

Optimizing Iron Chelation Therapy with Deferasirox for Non-Transfusion-Dependent Thalassemia Patients: 1-Year Results from the Phase IV, Open-Label Thetis Study

Ali T Taher, M Domenica Cappellini, Yesim Aydinok, John B. Porter, Zeynep Karakas, Vip Viprakasit, Noppadol Siritanaratkul, Antonis Kattamis, Candace Wang, Zewen Zhu, Victor Joaquin, Marie José Uwamahoro, Yong-Rong Lai

Blood (2015) 126 (23): 2153.

https://doi.org/10.1182/blood.V126.23.2153.2153

Published: 2015

Journal Articles

Association of Liver Iron Concentration Levels with Myocardial T2* Responses in Transfusion-Dependent Thalassemia Major Patients Treated with Deferasirox and Deferoxamine- Extension of Cordelia Study

Dudley J Pennell, John B Porter, Antonio Piga, Jackie Han, Alexander Vorog, Yesim Aydinok

Blood (2015) 126 (23): 2155.

https://doi.org/10.1182/blood.V126.23.2155.2155

Published: 2015

Journal Articles

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Yesim Aydinok, Antonis Kattamis, M. Domenica Cappellini, Amal El-Beshlawy, Raffaella Origa, Mohsen Elalfy, Yurdanur Kilinç, Silverio Perrotta, Zeynep Karakas, Vip Viprakasit, Dany Habr, Niculae Constantinovici, Junwu Shen, John B. Porter

Blood (2015) 125 (25): 3868–3877.

https://doi.org/10.1182/blood-2014-07-586677

Published: 2015

Includes: Supplemental data

Journal Articles

Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with β Thalassemia Major Treated with Deferasirox for up to 3 Years

John B Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Amal El-Beshlawy, MD/Professor, Mohsen Elalfy, MD, Ali El-Ali, MD, Nathalie Barbier, M Domenica Cappellini, MD

Blood (2014) 124 (21): 4040.

https://doi.org/10.1182/blood.V124.21.4040.4040

Published: 2014

Journal Articles

ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study

Antonio G. Piga, MD, Silverio Perrotta, MD, Angela Melpignano, MD, Caterina Borgna-Pignatti, MD, Ersi Voskaridou, MD, Vincenzo Caruso, MD, Aldo Filosa, MD, Yesim Aydinok, MD, Carrie Condon, Dawn M. Wilson, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2014) 124 (21): 53.

https://doi.org/10.1182/blood.V124.21.53.53

Published: 2014

Journal Articles

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

John B Porter, MD, Mohsen Elalfy, MD, Ali T Taher, MD, Lee Lee Chan, MD, Szu-Hee Lee, MD, Pranee Sutcharitchan, MD, Yesim Aydinok, MD, Subhashish Chakravarty, PhD, Ali El-Ali, MD, Amal El-Beshlawy, MD/Professor

Blood (2014) 124 (21): 52.

https://doi.org/10.1182/blood.V124.21.52.52

Published: 2014

Journal Articles

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

John B Porter, MD, Ali T Taher, MD PhD, Yesim Aydinok, MD, Amal El-Beshlawy, MD/Professor, Mohsen El-Alfy, MD, Ali El-Ali, MD, Subhashish Chakravarty, PhD, M Domenica Cappellini, MD

Blood (2014) 124 (21): 1366.

https://doi.org/10.1182/blood.V124.21.1366.1366

Published: 2014

Journal Articles

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)

Dudley J. Pennell, John B. Porter, Antonio Piga, Yongrong Lai, Amal El-Beshlawy, Khawla M. Belhoul, Mohsen Elalfy, Akif Yesilipek, Yurdanur Kilinç, Tomasz Lawniczek, Dany Habr, Marianne Weisskopf, Yiyun Zhang, Yesim Aydinok

Blood (2014) 123 (10): 1447–1454.

https://doi.org/10.1182/blood-2013-04-497842

Published: 2014

Includes: Supplemental data

Journal Articles

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Yesim Aydinok, MD, Antonis Kattamis, MD, M Domenica Cappellini, MD, Amal El-Beshlawy, MD, Raffaella Origa, MD, Mohsen Elalfy, MD, Yurdanur Kilinç, MD, Silverio Perrotta, MD, Zeynep Karakas, MD, Vip Viprakasit, MD, Dany Habr, MD, Antje Wegener, MD, Junwu Shen, PhD, John B Porter, MD

Blood (2013) 122 (21): 2257.

https://doi.org/10.1182/blood.V122.21.2257.2257

Published: 2013

Journal Articles

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

John Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Maria D Cappellini, Antonis Kattamis, MD, Ali El-Ali, MD, Nicolas Martin, MS, Dudley Pennell, MD, FRCP

Blood (2013) 122 (21): 1016.

https://doi.org/10.1182/blood.V122.21.1016.1016

Published: 2013

NARROW

Systematic Literature Review of the Indirect Costs, Humanistic Burden, Patient or Caregiver Preference, and Qualitative Outcomes in Beta-Thalassemia

A Phase 2a Study Evaluating the Safety and Pharmacokinetics (PK) of Luspatercept in Pediatric Patients with Transfusion-Dependent β-Thalassemia (TDT)

Is Normal Growth and Development Achieved By Current Management Approaches to Thalassemia Major in the New Era?

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

Hemoglobin Utilization in Asplenic and Non-Splenectomized Transfusion Dependent Thalassemia Patients Supported with Pathogen Reduced Red Blood Cell Concentrates in a Phase 3 Study (SPARC)

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

A Randomised 1 Year Study Evaluating the Impact of Vitamin C Supplementation on Systemic Iron Parameters of Iron Overload in Thalassemia Major Patients on Long-Term Treatment with Deferasirox

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Efficacy and Safety of Deferasirox in Chinese Patients with Non-Transfusion-Dependent Thalassemia: 1-Year Results from the Thetis Study

Efficacy and Safety of Deferasirox Across Underlying Non-Transfusion-Dependent Thalassemia Syndromes: 1-Year Results from the Thetis Study

Optimizing Iron Chelation Therapy with Deferasirox for Non-Transfusion-Dependent Thalassemia Patients: 1-Year Results from the Phase IV, Open-Label Thetis Study

Association of Liver Iron Concentration Levels with Myocardial T2* Responses in Transfusion-Dependent Thalassemia Major Patients Treated with Deferasirox and Deferoxamine- Extension of Cordelia Study

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with β Thalassemia Major Treated with Deferasirox for up to 3 Years

ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only